FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Sandoz to Pay $479 Million in Generic Drug Price-Fixing Litigation

Sandoz reaches agreements totaling about $479 million to resolve most of its remaining exposure in long-running U.S. litigation alleging anticompetiti...

latest-news-card-1
Human Drugs

FDA Experts Back 'Operation Trialblazer' But Warn Agency Still Needs Stability

FDA regulatory experts support the agency's new "Operation Trialblazer" initiative as an important step toward accelerating drug development but cauti...

latest-news-card-1
Human Drugs

FDA Cites Australian Drug Manufacturer for Quality System, Testing Deficiencies

FDA cites Australian manufacturer Veganic SKN Limited for multiple current good manufacturing practice deficiencies following a 7/2025 inspection of i...

latest-news-card-1
Biologics

Draft Guidance on Biosimilar Container Closure Design

A new FDA draft guidance outlines how sponsors should develop and evaluate container closure systems and device components used with biosimilar and in...

latest-news-card-1
Human Drugs

Commentary Questions FDA's Drug Innovation Policies

A new Harvard Law School legal commentary argues that decades of policies designed to accelerate pharmaceutical innovation may have instead encouraged...

latest-news-card-1
Human Drugs

Guidance on Adhesion Testing for Generic Transdermal/Topical Drugs

FDA finalizes a guidance outlining how generic drug developers should evaluate the adhesion performance of transdermal and topical delivery systems.

latest-news-card-1
Human Drugs

Ziltivekimab Misses Endpoint in Cardiovascular Outcomes Trial

Novo Nordisk says its investigational anti-inflammatory drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events in a late-s...

latest-news-card-1
Human Drugs

Guidance on Skin Irritation Studies for Transdermal/Topical ANDAs

FDA issues a revised draft guidance updating its recommendations for how generic drug developers should evaluate the skin irritation and sensitization...

latest-news-card-1
Human Drugs

FDA Expands Pluvicto Approval to Earlier-Stage Prostate Cancer

FDA approves Novartis' Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adu...

latest-news-card-1
Biologics

Sen. Johnson Wants Covid Interviews with Former FDAers, Fauci

Sen. Ron Johnson asks to interview four former CBER officials and Anthony Fauci on the safety and efficacy of Covid vaccines.